Samsung Epis Holdings Q1 2026 Earnings
Analysis based on 6 articles · First reported Apr 23, 2026 · Last updated Apr 24, 2026
The strong Q1 2026 financial results from Samsung SDS and its subsidiary Samsung Biologics — Samsung Biologics, driven by biosimilar portfolio growth and new partnerships, are likely to positively impact investor confidence in the biotechnology and pharmaceutical sectors. The surpassing of guidance and strategic investments suggest a robust outlook for Samsung SDS, potentially leading to increased stock valuation.
Samsung SDS announced its first quarter 2026 financial results, reporting a consolidated revenue of KRW 453.9 billion and an operating profit of KRW 90.5 billion. Its subsidiary, Samsung Biologics — Samsung Biologics, was a key driver, posting a standalone revenue of KRW 454.9 billion and an operating profit of KRW 144.0 billion, representing year-over-year increases of 14% and 13% respectively. These results surpassed January 2025 guidance by over 10%. Kyung-Ah Kim, CEO of Samsung SDS, highlighted the continued momentum of Samsung Biologics — Samsung Biologics's biosimilar portfolio and new global partnerships. Key business updates include Samsung Biologics — Samsung Biologics's private label partnership with CVS Health for OSPOMYV, the 10th anniversary of BENEPALI in Europe, an expanded partnership with Novartis — Sandoz for biosimilar candidates, and the initiation of a Phase 1 clinical trial for its novel ADC candidate SBE303. Epis NexLab, another subsidiary, is focused on next-generation biotechnology platforms.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard